Reported Earlier, Dexcom Announces Stelo, The First Over-The-Counter Glucose Biosensor In The U.S., Is Now Available For Purchase Without A Prescription
Portfolio Pulse from Benzinga Newsdesk
Dexcom has launched Stelo, the first over-the-counter glucose biosensor in the U.S., available without a prescription. It targets adults with Type 2 diabetes not using insulin and those with prediabetes, providing 24/7 glucose insights via smartphone.
August 26, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dexcom's launch of Stelo, an over-the-counter glucose biosensor, could boost its market presence and revenue by targeting a broader audience, including those with Type 2 diabetes not using insulin.
The launch of Stelo as an over-the-counter product allows Dexcom to tap into a new market segment, potentially increasing sales and market share. This innovation could enhance Dexcom's competitive edge and drive short-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100